Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3376-3385

  Kupelian, Patrick A ^a   Elshaikh, Mohamed ^a   Reddy, Chandana A ^a   Zippe, Craig ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION DOSAGE;

EID: 0037102387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.01.150     Document Type: Article

References (29)

1. Radical surgery versus radiotherapy for adenocarcinoma of the prostate
2. More on the Uro-Oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate
3. The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients
4. Prostate cancer
5. Prognostic factors in prostate cancer: Prostate specific antigen - An important marker for prostate cancer treated by external beam radiotherapy
6. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy
7. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
8. Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy - Steeply increasing values characterize 80% of patients
9. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis
10. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer
11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores
12. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer
13. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate
14. External beam radiotherapy dose response of prostate cancer
15. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
16. Contemporary results of anatomic radical prostatectomy
17. Radical prostatectomy for clinical stage T1 and T2 prostate cancer
18. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
19. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution
20. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration
21. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy
22. A pretreatment nomogram for disease progression following conformal radiotherapy for prostate cancer
23. Dose selection for prostate cancer patients based on dose comparison and dose response studies
24. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
25. Comparison of long-term survival in men with clinically localized prostate cancer managed conservatively, with definitive radiation or radical prostatectomy
26. Impact of biochemical failure as a predictor of overall survival in men with localized prostate cancer treated with radiotherapy
27. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-Year results
28. Radical perineal prostatectomy: Oncological outcome during a 20-year period
29. Natural history of progression after PSA elevation following radical prostatectomy